俄罗斯早期 HER2 阴性高危乳腺癌和 BRCA1/2 突变患病率的非干预性前瞻性研究 (ERA)
一项多中心、单臂、非干预性、观察性、前瞻性研究,旨在评估俄罗斯 HER2 阴性高危早期乳腺癌患者的 BRCA1/2m 患病率、治疗方法和结果
(Neo)adjuvant treatment approaches and outcomes
研究概览
地位
条件
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Arkhangelsk、俄罗斯
- Research Site
-
Barnaul、俄罗斯
- Research Site
-
Belgorod、俄罗斯
- Research Site
-
Chelyabinsk、俄罗斯
- Research Site
-
Grozny、俄罗斯
- Research Site
-
Irkutsk、俄罗斯
- Research Site
-
Khanty-Mansiysk、俄罗斯
- Research Site
-
Krasnodar、俄罗斯
- Research Site
-
Krasnoyarsk、俄罗斯
- Research Site
-
Moscow、俄罗斯
- Research Site
-
Nal'chik、俄罗斯
- Research Site
-
Nyzhny Novgorod、俄罗斯
- Research Site
-
Ryazan、俄罗斯
- Research Site
-
Saint Petersburg、俄罗斯
- Research Site
-
Severodvinsk、俄罗斯
- Research Site
-
Sochi、俄罗斯
- Research Site
-
Ufa、俄罗斯
- Research Site
-
Vladivostok、俄罗斯
- Research Site
-
Yaroslavl、俄罗斯
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Study population will consist of early breast cancer HER2-negative patients with high risk of recurrence with available medical history, surgery or biopsy FFPE from primary tumor. It is estimated that approximately 750 patients will be enrolled in approximately 25 sites
描述
Inclusion Criteria:
-
Patients aged ≥ 18 years old
-. Signed ICF, including patient's consent for genetic testing specimens from primary tumor and blood samples
-
Early HER2-negative BC (stages 2 and 3)
-
Compliance with at least 1 of the criteria for BRCA1/2 testing in accordance with the clinical guidelines of the Ministry of Health of the Russian Federation
-
Unknown BRCAm status or negative BRCAm PCR test
-
Performed surgical treatment (not more than 7 months before inclusion)
-. High risk of recurrence according to one or more criteria:
- incomplete pathomorphological response (in case of neoadjuvant therapy)
- CPS-EG 3 scale score 3 and more (in case of neoadjuvant therapy)
- presence of ≥ 4 metastatic lymph nodes in HR+ pts (in case of only adjuvant therapy)
- ≥pT2 or ≥pN1 in TNBC pts (in case of only adjuvant therapy)
- Any other high risk criterion according to investigators opinion
-
The presence of postoperative or biopsy FFPE
Exclusion Criteria:
- Participation in another clinical study with an investigational product during the last 3 months
- Confirmation that the subject was already included in this study before
- Absence of a written informed consent form; Data erroneously collected from subjects for which written consent is not available, will not be included in or will be deleted from the study database
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The primary objective of this study is to determine the prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer
大体时间:3 years
|
The prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer will be presented as a number of missing and non-missing records, median, standard deviation, 95% confidence interval for median |
3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To describe treatment approaches of high-risk early HER2-negative breast cancer in routine practice in the general population, in the BRCAm and non-BRCAm population
大体时间:3 years
|
Demographics, clinical characteristics, and treatment approaches will be summarized using descriptive statistics. |
3 years
|
|
To determine invasive disease-free survival for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population
大体时间:3 years
|
The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis |
3 years
|
|
To determine 3-year OS for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population
大体时间:3 years
|
The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis |
3 years
|
|
To determine the prevalence of HRR mutations in HER2-negative breast cancer
大体时间:3 years
|
Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status |
3 years
|
|
To determine invasive disease-free survival in the HRRm population (including BRCA1/2)
大体时间:3 years
|
Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status |
3 years
|
|
To evaluate concordance between P53 expression and BRCAm
大体时间:3 years
|
Testing the archived tumour specimen and blood |
3 years
|
|
To assess the quality of life in patients with various types of adjuvant systemic therapy
大体时间:3 years
|
completed WHOQOL-BREF questionnaire will be assessed |
3 years
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.